Cell therapy for heart failure: the need for a new therapeutic strategy

References

• Lloyd-Jones D, Adams RJ, Brown TM et al. Heart Disease and Stroke Statistics – 2010 Update: a report from the American Heart Association. Circulation121(7), e46–e215 (2010).
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure: physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol.54(19), 1747–1762 (2009).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med.327(10), 678–684 (1992).
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Braunwald E, Moye LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl J. Med.327(10), 669–677 (1992).
   PubMed Web of Science ®Google Scholar
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N. Engl J. Med.327(10), 685–691 (1992).
   PubMed Web of Science ®Google Scholar
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl J. Med.325(5), 293–302 (1991).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Gilbert EM, Abraham WT et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation94(11), 2807–2816 (1996).
   PubMed Web of Science ®Google Scholar
• Investigatros M-H. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). Lancet353(9169), 2001–2007 (1999).
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJS, Fowler MB et al. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med.344(22), 1651–1658 (2001).
   PubMed Web of Science ®Google Scholar
• Packer M, Poole-Wilson PA, Armstrong PW et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation100(23), 2312–2318 (1999).
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med.348(14), 1309–1321 (2003).
   PubMed Web of Science ®Google Scholar
• Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N. Engl. J. Med.341(10), 709–717 (1999).
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G; the Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med.345(23), 1667–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Anand PI, McMurray PJ, Cohn PJN et al. Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet364(9431), 347–354 (2004).
   PubMed Web of Science ®Google Scholar
• Rogers JG, Butler J, Lansman SL et al. Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTREPID trial. J. Am. Coll. Cardiol.50(8), 741–747 (2007).
   PubMed Web of Science ®Google Scholar
• Birks EJ, Tansley PD, Hardy J et al. Left ventricular assist device and drug therapy for the reversal of heart failure. N. Engl. J. Med.355(18), 1873–1884 (2006).
   PubMed Web of Science ®Google Scholar
• Abraham WT, Fisher WG, Smith AL et al. Cardiac resynchronization in chronic heart failure. N. Engl. J. Med.346(24), 1845–1853 (2002).
   PubMed Web of Science ®Google Scholar
• Abraham WT, Young JB, Leon AR et al. Effects of cardiac resynchronization on disease progression in patients with left ventricular systolic dysfunction, an indication for an implantable cardioverter-defibrillator, and mildly symptomatic chronic heart failure. Circulation110(18), 2864–2868 (2004).
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxon LA, Boehmer J et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N. Engl. J. Med.350(21), 2140–2150 (2004).
   PubMed Web of Science ®Google Scholar
• Cleland JGF, Daubert J-C, Erdmann E et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med.352(15), 1539–1549 (2005).
   PubMed Web of Science ®Google Scholar
• St John Sutton MG, Plappert T, Abraham WT et al. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation107(15), 1985–1990 (2003).
   PubMed Web of Science ®Google Scholar
• Fukuda K, Yuasa S. Stem cells as a source of regenerative cardiomyocytes. Circ. Res.98(8), 1002–1013 (2006).
   PubMed Web of Science ®Google Scholar
• Thomson JA, Itskovitz-Eldor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science282, 1145–1147 (1998).
   PubMed Web of Science ®Google Scholar
• Blocklet D, Toungouz M, Berkenboom G et al. Myocardial homing of nonmobilized peripheral-blood CD34+ cells after intracoronary injection. Stem Cells24(2), 333–336 (2006).
   PubMed Web of Science ®Google Scholar
• Hofmann M, Wollert KC, Meyer GP et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation111(17), 2198–2202 (2005).
   PubMed Web of Science ®Google Scholar
• Kang W, Kang H-J, Kim H, Chung J, Lee M, Lee D. Tissue distribution of 18F-FDG-labeled peripheral hematopoietic stem cells after intracoronary administration in patients with myocardial infarction. J. Nucl. Med.47, 1295–1301 (2006).
   PubMed Web of Science ®Google Scholar
• Penicka M, Widimsky P, Kobylka P, Kozak T, Lang O. Early tissue distribution of bone marrow mononuclear cells after transcoronary transplantation in a patient with acute myocardial infarction. Circulation112(4), e63–65 (2005).
   Google Scholar
• Schachinger V, Aicher A, Dobert N et al. Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium. Circulation118(14), 1425–1432 (2008).
   PubMed Web of Science ®Google Scholar
• Schots R, De Keulenaer G, Schoors D et al. Evidence that intracoronary-injected CD133+ peripheral blood progenitor cells home to the myocardium in chronic postinfarction heart failure. Exp. Hematol.35(12), 1884–1890 (2007).
   PubMed Web of Science ®Google Scholar
• Brasselet C, Morichetti MC, Messas E et al. Skeletal myoblast transplantation through a catheter-based coronary sinus approach: an effective means of improving function of infarcted myocardium. Eur. Heart J.26(15), 1551–1556 (2005).
   PubMed Web of Science ®Google Scholar
• Hare JM, Traverse JH, Henry TD et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (Prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol.54(24), 2277–2286 (2009).
   PubMed Web of Science ®Google Scholar
• Freyman T, Polin G, Osman H et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur. Heart J.27(9), 1114–1122 (2006).
   PubMed Web of Science ®Google Scholar
• Hou D, Youssef EA-S, Brinton TJ et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation112(Suppl. 9), I150–I156 (2005).
   PubMed Web of Science ®Google Scholar
• Perin EC, Silva GV, Assad JAR et al. Comparison of intracoronary and transendocardial delivery of allogeneic mesenchymal cells in a canine model of acute myocardial infarction. J. Mol. Cell. Cardiol.44(3), 486–495 (2008).
   PubMed Web of Science ®Google Scholar
• Bartunek J, Sherman W, Vanderheyden M, Fernandez-Aviles F, Wijns W, Terzic A. Delivery of biologics in cardiovascular regerative medicine. Clin. Pharmacol. Ther.85(5), 548–552 (2009).
   PubMed Web of Science ®Google Scholar
• Sekiya S, Shimizu T, Yamato M, Kikuchi A, Okano T. Bioengineered cardiac cell sheet grafts have intrinsic angiogenic potential. Biochem. Biophys. Res. Commun.341(2), 573–582 (2006).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Shimizu T, Yamato M et al. Fibroblast sheets co-cultured with endothelial progenitor cells improve cardiac function of infarcted hearts. J. Artif. Organs11(3), 141–147 (2008).
   PubMed Web of Science ®Google Scholar
• Masuda S, Shimizu T, Yamato M, Okano T. Cell sheet engineering for heart tissue repair. Adv. Drug Deliv. Rev.60(2), 277–285 (2008).
   PubMed Web of Science ®Google Scholar
• Badie N, Sattewhite L, Bursac N. A method to replicate the microstructure of heart tissue in vitro using DTMRI-based micropatterning. Ann. Biomed. Eng.37(12), 1512–1521 (2009).
   Google Scholar
• Bursac N. Cardiac tissue engineering using stem cells. IEEE Eng. Med. Biol. Mag.28(2), 82–89 (2009).
   Google Scholar
• Tongers J, Webber MJ, Losordo DW. Bioengineering to enhance progenitor cell therapeutics. Tex. Heart Inst. J.36(2), 140–144 (2009).
   PubMed Web of Science ®Google Scholar
• Assmus B, Honold J, Schachinger V et al. Transcoronary transplantation of progenitor cells after myocardial infarction. N. Engl. J. Med.355(12), 1222–1232 (2006).
   PubMed Web of Science ®Google Scholar
• Assmus B, Schachinger V, Teupe C et al. Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI). Circulation106, 3009–3017 (2002).
   PubMed Web of Science ®Google Scholar
• Bartunek J, Vanderheyden M, Vandekerckhove B et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation112(Suppl. 9), I178–I183 (2005).
   PubMed Web of Science ®Google Scholar
• Britten M, Abolmaali ND, Assmus B et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI). Circulation108(18), 2212–2218 (2003).
   PubMed Web of Science ®Google Scholar
• Chen S-l, Fang W-w, Ye F et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol.94(1), 92–95 (2004).
   PubMed Web of Science ®Google Scholar
• Dobert N, Britten M, Assmus B et al. Transplantation of progenitor cells after reperfused acute myocardial infarction: evaluation of perfusion and myocardial viability with FDG-PET and thallium SPECT. Eur. J. Nuc. Med. Mol. Imaging31(8), 1146–1151 (2004).
   PubMed Web of Science ®Google Scholar
• Ge J, Li Y, Qian J et al. Efficacy of emergent transcatheter transplantation of stem cells for treatment of acute myocardial infarction (TCT-STAMI). Heart92(12), 1764–1767 (2006).
   PubMed Web of Science ®Google Scholar
• Huikuri HV, Kervinen K, Niemela M et al. Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction. Eur. Heart J.29(22), 2723–2732 (2008).
   PubMed Web of Science ®Google Scholar
• Janssens S, Dubois C, Bogaert J et al. Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet367(9505), 113–121 (2006).
   PubMed Web of Science ®Google Scholar
• Kang H-J, Kim H-S, Zhang S-Y et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilized with granulocyte-colony stimulating factor on left ventricular systolic function and restensis after coronary stenting in myocardial infarction: the MAGIC Cell randomised clinical trial. Lancet363, 751–756 (2004).
   PubMed Web of Science ®Google Scholar
• Kang H-J, Lee H-Y, Na S-H et al. Differential effect of intracoronary infusion of mobilized peripheral blood stem cells by granulocyte colony-stimulating factor on left ventricular function and remodeling in patients with acute myocardial infarction versus old myocardial infarction: the MAGIC Cell-3-DES randomized, controlled trial. Circulation114(Suppl. 1), I145–I151 (2006).
   PubMed Web of Science ®Google Scholar
• Kucia M, Dawn B, Hunt G et al. Cells expressing early cardiac markers reside in the bone marrow and are mobilized into the peripheral blood after myocardial infarction. Circ. Res.95(12), 1191–1199 (2004).
   PubMed Web of Science ®Google Scholar
• Li Z, Ming Z, Yuan-zhe J et al. The clinical study of autologous peripheral blood stem cell transplantation by intracoronary infusion in patients with acute myocardial infarction (AMI). Int. J. Cardiol.115(1), 52–56 (2007).
   PubMed Web of Science ®Google Scholar
• Lunde K, Solheim S, Aakhus S et al. Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N. Engl. J. Med.355, 1199–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Lunde K, Solheim S, Forfang Kr et al. Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months’ follow-up. J. Am. Coll. Cardiol.51(6), 674–676 (2008).
   PubMed Web of Science ®Google Scholar
• Meluzín J, Mayer J, Groch L et al. Autologous transplantation of mononuclear bone marrow cells in patients with acute myocardial infarction: the effect of the dose of transplanted cells on myocardial function. Am. Heart J.152(5), 975.e979–975.e915 (2006).
   Google Scholar
• Nijveldt R, Hirsch A, Van der Vleuten P et al. Intracoronary infusion of mononuclear cells after primary percutaneous coronary intervention: the HEBE trial. Circulation118(22), 2316 (2008).
   Google Scholar
• Schachinger V, Erbs S, Elsasser A et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N. Engl. J. Med.355(12), 1210–1221 (2006).
   PubMed Web of Science ®Google Scholar
• Schachinger V, Erbs S, Elsasser A et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur. Heart J.27(23), 2775–2783 (2006).
   PubMed Web of Science ®Google Scholar
• Stamm C, Westphal B, Kleine H-D et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet361, 45–46 (2003).
   PubMed Web of Science ®Google Scholar
• Strauer BE, Brehm M, Zeus T et al. Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT study. J. Am. Coll. Cardiol.46(9), 1651–1658 (2005).
   PubMed Web of Science ®Google Scholar
• Strauer BE, Brehm M, Zeus T et al. Repair of infarcted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation106, 1913–1918 (2002).
   PubMed Web of Science ®Google Scholar
• Tendera M, Wojakowski W, Ruzyllo W et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) trial. Eur. Heart J.30(11), 1313–1321 (2009).
   PubMed Web of Science ®Google Scholar
• Wollert KC, Meyer GP, Lotz J et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet364, 141–148 (2004).
   PubMed Web of Science ®Google Scholar
• Yousef M, Schannwell CM, Köstering M, Zeus T, Brehm M, Strauer BE. The BALANCE study: clinical benefit and long-term outcome after intracoronary autologous bone marrow cell transplantation in patients with acute myocardial infarction. J. Am. Coll. Cardiol.53(24), 2262–2269 (2009).
   PubMed Web of Science ®Google Scholar
• Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N. Engl. J. Med.344(21), 1594–1602 (2001).
   PubMed Web of Science ®Google Scholar
• Kaptchuk TJ, Goldman P, Stone DA, Stason WB. Do medical devices have enhanced placebo effects? J. Clin. Epidemiol.53(8), 786–792 (2000).
   PubMed Web of Science ®Google Scholar
• Ruan W, Pan C, Huang G, Li Y, Ge J, Shu X. Assessment of left ventricular segmental function after autologous bone marrow sten cells transplantation in patients with acute myocardial infarction by tissue tracking and strain imaging. Chin. Med. J. (Engl.)118, 1175–1181 (2005).
   PubMed Web of Science ®Google Scholar
• Hendrikx M, Hensen K, Clijsters C et al. Recovery of regional but not global contractile function by the direct intramyocardial autologous bone marrow transplantation: results from a randomized controlled clinical trial. Circulation114(Suppl. 1), I101–I107 (2006).
   Google Scholar
• Meyer GP, Wollert KC, Lotz J et al. Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months’ follow-up data from the randomized, controlled BOOST (Bone Marrow Transfer to Enhance ST-Elevation Infarct Regeneration) trial. Circulation113(10), 1287–1294 (2006).
   PubMed Web of Science ®Google Scholar
• Abdel-Latif A, Bolli R, Tleyjeh IM et al. Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch. Intern. Med.167(10), 989–997 (2007).
   PubMed Web of Science ®Google Scholar
• Hristov M, Heussen N, Schober A, Weber C. Intracoronary infusion of autologous bone marrow cells and left ventricular function after acute myocardial infarction: a meta-analysis. J. Cell. Mol. Med.10(3), 727–733 (2006).
   PubMed Web of Science ®Google Scholar
• Lipinski MJ, Biondi-Zoccai GGL, Abbate A et al. Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J. Am. Coll. Cardiol.50(18), 1761–1767 (2007).
   PubMed Web of Science ®Google Scholar
• Burt RK, Loh Y, Pearce W et al. Clinical applications of blood-derived and marrow-derived stem cells for nonmalignant diseases. JAMA299(8), 925–936 (2008).
   PubMed Web of Science ®Google Scholar
• Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur. Heart J.28(6), 766–772 (2007).
   PubMed Web of Science ®Google Scholar
• Jolicoeur EM, Granger CB, Fakunding JL et al. Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. Am. Heart J.153(5), 732–742 (2007).
   PubMed Web of Science ®Google Scholar
• Kissel CK, Lehmann R, Assmus B et al. Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure. J. Am. Coll. Cardiol.49(24), 2341–2349 (2007).
   PubMed Web of Science ®Google Scholar
• Assmus B, Fischer-Rasokat U, Honold J et al. Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD registry. Circ. Res.100(8), 1234–1241 (2007).
   PubMed Web of Science ®Google Scholar
• Heeschen C, Lehmann R, Honold J et al. Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease. Circulation109, 1615–1622 (2004).
   PubMed Web of Science ®Google Scholar
• Amado LC, Saliaris AP, Schuleri KH et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc. Natl Acad. Sci. USA102(32), 11474–11479 (2005).
   PubMed Web of Science ®Google Scholar
• Gnecchi M, He H, Liang OD et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med.11(4), 367–368 (2005).
   PubMed Web of Science ®Google Scholar
• Gnecchi M, He H, Noiseux N et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J.20(6), 661–669 (2006).
   PubMed Web of Science ®Google Scholar
• Mangi AA, Noiseux N, Kong D et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med.9(9), 1195–1201 (2003).
   PubMed Web of Science ®Google Scholar
• Traverse JH, Henry TD, Vaughn DE et al. Rationale and design for TIME: a Phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. Am. Heart J.158(3), 356–363 (2009).
   PubMed Web of Science ®Google Scholar
• Blatt A, Cotter G, Leitman M et al. Intracoronary administration of autologous bone marrow mononuclear cells after induction of short ischemia is safe and may improve hibernation and ischemia in patients with ischemic cardiomyopathy. American Heart Journal150(5), 986.e1–986.e7 (2005).
   PubMedGoogle Scholar
• Fuchs S, Satler LF, Kornowski R et al. Catheter-based autologous bone marrow myocardial injection in no-option patients with advanced coronary artery disease. J. Am. Coll. Cardiol.41, 1721–1724 (2003).
   PubMed Web of Science ®Google Scholar
• Hamano K, Nishida M, Hirata K et al. Local implantation of autologous bone marrow cells for therapeutic angiogenesis in patients with ischemic heart disease. Jpn Circ. J.65, 845–847 (2001).
   PubMedGoogle Scholar
• Losordo DW, Schatz RA, White CJ et al. Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a Phase I/IIa double-blind, randomized controlled trial. Circulation115(25), 3165–3172 (2007).
   PubMed Web of Science ®Google Scholar
• Tse H-F, Kwong Y-L, Chan JKF, Lo G, Ho C-L, Lau C-P. Angiogenesis in ischaemic mocardium by intramyocardial autologous bone marrow mononuclear cell transplantation. Lancet361, 47–49 (2003).
   PubMed Web of Science ®Google Scholar
• Losordo DW, Henry T, Schatz RA et al. Abstract 5638: Autologous CD34+ cell therapy for refractory angina: 12 month results of the Phase II ACT34-CMI Study. Circulation120, S1132 (2009).
   Google Scholar
• Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J. Am. Coll. Cardiol.48(3), 566–575 (2006).
   PubMed Web of Science ®Google Scholar
• Pompili V. SEACOAST: Results of CD133+ cells for CMI. Presented at: The Third International Conference for Cell Therapy for Cardiovascular Disease. New York, NY, USA, 17–19 January 2007.
   Google Scholar
• Galinanes M, Loubani M, Davies J, Chin D, Pasi J, Bell PR. Autotransplantation of unmanipulated bone marrow into scarred myocardium is safe and enhances cardiac function in humans. Cell Transplant.13(1), 7–13 (2004).
   PubMed Web of Science ®Google Scholar
• Gao LR, Wang ZG, Zhu ZM et al. Effect of intracoronary transplantation of autologous bone marrow-derived mononuclear cells on outcomes of patients with refractory chronic heart failure secondary to ischemic cardiomyopathy. Am. J. Cardiol.98(5), 597–602 (2006).
   PubMed Web of Science ®Google Scholar
• Hill JM, Bartunek J. The end of granulocyte colony-stimulating factor in acute myocardial infarction? Reaping the benefits beyond cytokine mobilization Circulation113(16), 1926–1928 (2006).
   PubMed Web of Science ®Google Scholar
• Ozbaran M, Omay SB, Nalbantgil S et al. Autologous peripheral stem cell transplantation in patients with congestive heart failure due to ischemic heart disease. Eur. J. Cardiothorac. Surg.25, 342–351 (2004).
   PubMed Web of Science ®Google Scholar
• Patel AN, Geffner L, Vina RF et al. Surgical treatment for congestive heart failure with autologous adult stem cell transplantation: a prospective randomized study. J. Thorac. Cardiovasc. Surg.130(6), 1631 (2005).
   PubMed Web of Science ®Google Scholar
• Perin EC, Dohmann HFR, Borojevic R et al. Transendocardial, autologous bone marrow cell transplantation for severe chronic ischemic heart failure. Circulation107, 2294–2302 (2003).
   PubMed Web of Science ®Google Scholar
• Perin EC, Silva GV, Zheng Y et al. Abstract 3502: First in man transendocardial injection of autologous aldehyde dehydrogenase-bright cells in heart failure patients (FOCUS-Bright). Circulation120(18 MeetingAbstracts), S812 (2009).
   Google Scholar
• Dib N, Henry T, DeMaria A et al. Abstract 3493: The first US study to assess the feasibility and safety of endocardial delivery of allogenic mesenchymal precursor cells in patient with heart failure: three-month interim analysis. Circulation120(18), S810b (2009).
   Google Scholar
• Schannwell CM, Yousef M, Basalyk CM et al. Abstract 2390: Dusseldorfer-ABCD trial (Autologous Bone Marrow Cells in Dilated Cardiomyopathy). Circulation118(18), S716 (2008).
   Google Scholar
• Seth S, Narang R, Bhargava B et al. Percutaneous intracoronary celullar cardiomyoplasty for nonischemic cardiomyopathy: clinical and histopathological results: the first-in-man ABCE (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial. J. Am. Coll. Cardiol.48, 2350–2351 (2006).
   PubMed Web of Science ®Google Scholar
• Bearzi C, Rota M, Hosoda T et al. Human cardiac stem cells. Proc. Natl Acad. Sci. USA104(35), 14068–14073 (2007).
   PubMed Web of Science ®Google Scholar
• Urbanek K, Torella D, Sheikh F et al. Myocardial regeneration by activation of multipotent cardiac stem cells in ischemic heart failure. Proc. Natl Acad. Sci. USA102(24), 8692–8697 (2005).
   PubMed Web of Science ®Google Scholar
• Manginas A, Goussetis E, Koutelou M et al. Pilot study to evaluate the safety and feasibility of intracoronary CD133+ and CD133+ CD34+ cell therapy in patients with nonviable anterior myocardial infarction. Catheter. Cardiovasc. Interv.69(6), 773–781 (2007).
   PubMed Web of Science ®Google Scholar
• Archundia A, Aceves J, Lopez-Hernandez M et al. Direct cardiac injection of G-CSF mobilized bone-marrow stem-cells improves ventricular function in Old myocardial infarction. Life Sci.79, 279–283 (2005).
   Google Scholar
• Menasche P, Hagege AA, Vilquin J-T et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol.41(7), 1078–1083 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor DA, Atkins BZ, Hungsprugs P et al. Regenerating functional myocardium: Improved performance after skeletal myobalst transplantation. Nat. Med.4(8), 929–933 (1998).
   PubMed Web of Science ®Google Scholar
• Scorsin M, Hagège A, Vilquin J-T et al. Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on postinfarction left ventricular function. J. Thorac. Cardiovasc. Surg.119(6), 1169–1175 (2000).
   PubMed Web of Science ®Google Scholar
• Law P. First human heart myoblast allograft. Circulation110(Suppl. III), 39 (2004).
   Web of Science ®Google Scholar
• Taylor DA. Cell-based myocardial repair: how should we proceed? Int. J. Cardiol.95(Suppl. 1), S8–S12 (2004).
   Google Scholar
• Dib N, Michler RE, Pagani FD et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation112(12), 1748–1755 (2005).
   PubMed Web of Science ®Google Scholar
• Gavira JJ, Herreros Js, Perez A et al. Autologous skeletal myoblast transplantation in patients with nonacute myocardial infarction: 1-year follow-up. J. Thorac. Cardiovasc. Surg.131(4), 799–804 (2006).
   PubMed Web of Science ®Google Scholar
• Hagege AA, Marolleau J-P, Vilquin J-T et al. Skeletal myoblast transplantation in ischemic heart failure: long-term follow-up of the first Phase I cohort of patients. Circulation114(Suppl. 1), I108–I113 (2006).
   PubMed Web of Science ®Google Scholar
• He K-L, Yi G-H, Sherman W et al. Autologous skeletal myoblast transplantation improved hemodynamics and left ventricular function in chronic heart failure dogs. J. Heart Lung Transplant.24(11), 1940–1949 (2005).
   PubMed Web of Science ®Google Scholar
• Herreros J, Prosper F, Perez A et al. Autologous intramyocardial injection of cultured skeletal muscle-derived stem cells in patients with non-acute myocardial infarction. Eur. Heart J.24(22), 2012–2020 (2003).
   PubMed Web of Science ®Google Scholar
• Ince Hs, Petzsch M, Rehders TC, Chatterjee T, Nienaber CA. Transcatheter transplantation of autologous skeletal myoblasts in postinfarction patients with severe left ventricular dysfunction. J. Endovasc. Ther.11(6), 695–704 (2004).
   PubMed Web of Science ®Google Scholar
• Siminiak T, Fiszer D, Jerzykowska O et al. Percutaneous trans-coronary-venous transplantation of autologous skeletal myoblasts in the treatment of post-infarction myocardial contractility impairment: the POZNAN trial. Eur. Heart J.26(12), 1188–1195 (2005).
   PubMed Web of Science ®Google Scholar
• Siminiak T, Kalawski R, Fiszer D et al. Autologous skeletal myoblast transplantation for the treatment of postinfarction myocardial injury: Phase I clinical study with 12 months of follow-up. Am. Heart J.148(3), 531–537 (2004).
   PubMed Web of Science ®Google Scholar
• Smits PC, van Geuns R-JM, Poldermans D et al. Catheter-based intramyocardial injection of autologous skeletal myoblasts as a primary treatment of ischemic heart failure: clinical experience with six-month follow-up. J. Am. Coll. Cardiol.42(12), 2063–2069 (2003).
   PubMed Web of Science ®Google Scholar
• Chachques JC, Duarte F, Cattadori B et al. Angiogenic growth factors and/or cellular therapy for myocardial regeneration: a comparative study. J. Thorac. Cardiovasc. Surg.128(2), 245–253 (2004).
   PubMed Web of Science ®Google Scholar
• Sherman W. MYOHEART US Phase I study: 12 month data. Presented at: The Fifth Annual Conference on Cell Therapy for Cardiovascular Disease. New York, NY, USA, 13–16 January 2009.
   Google Scholar
• Dib N, Dinsmore J, Lababidi Z et al. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAUSMIC study). JACC Cardiovasc. Interv.2(1), 9–16 (2009).
   PubMed Web of Science ®Google Scholar
• Abraham MR, Henrikson CA, Tung L et al. Antiarrhythmic engineering of skeletal myoblasts for cardiac transplantation. Circ. Res.97(2), 159–167 (2005).
   PubMed Web of Science ®Google Scholar
• Serruys P. Final results of a Phase II, randomized, open-label trial to evaluate intramyocardial autologous skeletal myoblast transplantation in congestive heart failure patients: the SEISMIC trial. In: American College of Cardiology Scientific Sessions – Late Breaking Clinical Trials. Chicago, IL, USA (2008).
   Google Scholar
• Povsic T, Henry T, Taussig A et al. MARVEL-1: a double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of myocell implantation by a catheter delivery system in congestive heart failure patients post myocardial infarction(s). J. Card. Fail.15(9), 814–815 (2009).
   Google Scholar
• Menasche P, Alfieri O, Janssens S et al. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation117(9), 1189–1200 (2008).
   PubMed Web of Science ®Google Scholar
• Muller P, Pfeiffer P, Koglin J et al. Cardiomyocytes of noncardiac origin in myocardial biopsies of human transplanted hearts. Circulation106, 31–35 (2002).
   PubMed Web of Science ®Google Scholar
• Quaini F, Urbanek K, Beltrami AP et al. Chimerism of the transplanted heart. N. Eng. J. Med.346(1), 5–15 (2002).
   PubMed Web of Science ®Google Scholar
• Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature410, 701–705 (2001).
   PubMed Web of Science ®Google Scholar
• Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature428, 668–673 (2004).
   PubMed Web of Science ®Google Scholar
• Murry CE, Soonpaa MH, Reinecke H et al. Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial infarcts. Nature328, 664–668 (2004).
   Web of Science ®Google Scholar
• Dimmeler S, Burchfield J, Zeiher AM. Cell-based therapy of myocardial infarction. Arterioscler. Thromb. Vasc. Biol.28(2), 208–216 (2008).
   PubMed Web of Science ®Google Scholar
• Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ. Res.103(11), 1204–1219 (2008).
   PubMed Web of Science ®Google Scholar
• Uemura R, Xu M, Ahmad N, Ashraf M. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ. Res.98(11), 1414–1421 (2006).
   PubMed Web of Science ®Google Scholar
• Wollert KC, Drexler H. Clinical applications of stem cells for the heart. Circ. Res.96(2), 151–163 (2005).
   PubMed Web of Science ®Google Scholar
• Anversa P, Leri A, Kajstura J. Cardiac regeneration. J. Am. Coll. Cardiol.47(9), 1769–1776 (2006).
   PubMed Web of Science ®Google Scholar
• Beltrami AP, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell114(6), 763–776 (2003).
   PubMed Web of Science ®Google Scholar
• Beltrami AP, Urbanek K, Kajstura J et al. Evidence that human cardiac myocytes divide after myocardial infarction. N. Engl. J. Med.344(23), 1750–1757 (2001).
   PubMed Web of Science ®Google Scholar
• Kajstura J, Rota M, Whang B et al. Bone marrow cells differentiate in cardiac cell lineages after infarction independently of cell fusion. Circ. Res.96(1), 127–137 (2005).
   PubMed Web of Science ®Google Scholar
• Messina E, De Angelis L, Frati G et al. Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ. Res.95(9), 911–921 (2004).
   PubMed Web of Science ®Google Scholar
• Smith RR, Barile L, Cho HC et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation115(7), 896–908 (2007).
   PubMed Web of Science ®Google Scholar
• Fransioli J, Bailey B, Gude NA et al. Evolution of the c-kit-positive cell response to pathological challenge in the myocardium. Stem Cells26(5), 1315–1324 (2008).
   PubMed Web of Science ®Google Scholar
• Laugwitz K-L, Moretti A, Lam J et al. Postnatal isl1+ cardioblasts enter fully differentiated cardiomyocyte lineages. Nature433(7026), 647–653 (2005).
   PubMed Web of Science ®Google Scholar
• Matsuura K, Nagai T, Nishigaki N et al. Adult cardiac Sca-1-positive cells differentiate into beating cardiomyocytes. J. Biol. Chem.279(12), 11384–11391 (2004).
   PubMed Web of Science ®Google Scholar
• Hierlihy AM, Seale P, Lobe CG, Rudnicki MA, Megeney LA. The post-natal heart contains a myocardial stem cell population. FEBS Lett.530(1–3), 239–243 (2002).
   PubMed Web of Science ®Google Scholar
• Martin CM, Meeson AP, Robertson SM et al. Persistent expression of the ATP-binding cassette transporter, ABCG2, identifies cardiac SP cells in the developing and adult heart. Dev. Biol.265(1), 262–275 (2004).
   PubMed Web of Science ®Google Scholar
• Smith RR, Barile L, Messina E, Marban E. Stem cells in the heart: what’s the buzz all about? Part I: preclinical considerations. Heart Rhythm5, 749–757 (2008).
   PubMed Web of Science ®Google Scholar
• Smith RR, Barile L, Messina E, Marban E. Stem cells in the heart: what’s the buzz all about? Part 2: arrhythmic risks and clinical studies. Heart Rhythm5, 880–887 (2008).
   PubMed Web of Science ®Google Scholar
• Oh H, Bradfute SB, Gallardo TD et al. Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc. Natl Acad. Sci. USA100(21), 12313–12318 (2003).
   PubMed Web of Science ®Google Scholar
• Li Z, Lee A, Huang M et al. Imaging Survival and function of transplanted cardiac resident stem cells. J. Am. Coll. Cardiol.53(14), 1229–1240 (2009).
   PubMed Web of Science ®Google Scholar
• Tomita S, Li R-K, Weisel RD et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation100(90002), II247–II256 (1999).
   PubMed Web of Science ®Google Scholar
• Makino S, Fukuda K, Miyoshi S et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J. Clin. Invest.103(5), 697–705 (1999).
   PubMed Web of Science ®Google Scholar
• Mazhari R, Hare JM. Advances in cell-based therapy for structural heart Disease. Prog. Cardiovasc. Dis.49(6), 387–395 (2007).
   PubMed Web of Science ®Google Scholar
• Mazhari R, Hare JM. Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nat. Clin. Pract. Cardiovasc. Med.4 (Suppl. 1), S21–S26 (2007).
   PubMedGoogle Scholar
• Schuleri KH, Amado LC, Boyle AJ et al. Early improvement in cardiac tissue perfusion due to mesenchymal stem cells. Am. J. Physiol. Heart Circ. Physiol.294(5), H2002–H2011 (2008).
   PubMed Web of Science ®Google Scholar
• Toma C, Pittenger MF, Cahill KS, Byrne BJ, Kessler PD. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation105(1), 93–98 (2002).
   PubMed Web of Science ®Google Scholar
• Liechty K, MacKenzie T, Shaaban A et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation ater in utero transplantation in sheep. Nat. Med.6, 1282–1286 (2000).
   PubMed Web of Science ®Google Scholar
• Boheler K, Czyz J, Tweedie D, Yang H-T, Anisimov SV, Wobus AM. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ. Res.91, 189–201 (2002).
   PubMed Web of Science ®Google Scholar
• Swijnenburg R-J, Tanaka M, Vogel H et al. Embryonic stem cell immunogenicity increases upon differentiation after transplantation into ischemic myocardium. Circulation112(Suppl. 9), I166–I172 (2005).
   PubMed Web of Science ®Google Scholar
• Singla DK, Hacker TA, Ma L et al. Transplantation of embryonic stem cells into the infarcted mouse heart: formation of multiple cell types. J. Mol. Cell. Cardiol.40(1), 195–200 (2006).
   PubMed Web of Science ®Google Scholar
• Solter D. From teratomacrcinomas to embryonic stem cells and beyond: a history of embryonic stem cell research. Nat. Rev. Genet.7(4), 319–327 (2006).
   PubMed Web of Science ®Google Scholar
• Tomescot A, Leschik J, Bellamy V et al. Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats. Stem Cells25(9), 2200–2205 (2007).
   PubMed Web of Science ®Google Scholar
• Behfar A, Faustino RS, Arrell DK, Dzeja PP, Perez-Terzic C, Terzic A. Guided stem cell cardiopoiesis: discovery and translation. J. Mol. Cell. Cardiol.45(4), 523–529 (2008).
   PubMed Web of Science ®Google Scholar
• Behfar A, Perez-Terzic C, Faustino RS et al. Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J. Exp. Med.204(2), 405–420 (2007).
   PubMed Web of Science ®Google Scholar
• Kucia M, Halasa M, Wysoczynski M et al. Morphological and molecular characterization of a novel population of CXCR4+ SSEA-4+ ct-4+ very small embyonic-like cells purified from human cord blood: preliminary report. Leukemia21, 297–303 (2007).
   PubMed Web of Science ®Google Scholar
• Kucia M, Reca R, Campbell F et al. A population of very small embryonic-like (VSEL) CXCR4+SSEA-1+Oct-4+ stem cells identified in adult bone marrow. Leukemia20, 857–869 (2006).
   PubMed Web of Science ®Google Scholar
• Zuba-Surma EK, Kucia M, Abdel-Latif A et al. Morphological characterization of very small embryonic-like stem cells (VSELs) by ImageStream system analysis. J. Cell. Mol. Med.12(1), 292–303 (2008).
   PubMed Web of Science ®Google Scholar
• Zuba-Surma EK, Kucia M, Dawn B, Guo Y, Ratajczak MZ, Bolli R. Bone marrow-derived pluripotent very small embryonic-like stem cells (VSELs) are mobilized after acute myocardial infarction. J. Mol. Cell. Cardiol.44(5), 865–873 (2008).
   PubMed Web of Science ®Google Scholar
• Dawn B, Tiwari S, Kucia MJ et al. Transplantation of bone marrow-derived very small embryonic-like stem cells attenuates left ventricular dysfunction and remodeling after myocardial infarction. Stem Cells26(6), 1646–1655 (2008).
   PubMed Web of Science ®Google Scholar
• Kim B-O, Tian H, Prasongsukarn K et al. Cell transplantation improves ventricular function after a myocardial infarction: a preclinical study of human unrestricted somatic stem cells in a porcine model. Circulation112(Suppl. 9), I-96–I-104 (2005).
   Google Scholar
• Wu KH, Zhou B, Yu CT et al. Therapeutic potential of human umbilical cord derived stem cells in a rat myocardial infarction model. Ann. Thorac. Surg.83(4), 1491–1498 (2007).
   PubMed Web of Science ®Google Scholar
• Chiavegato A, Bollini S, Pozzobon M et al. Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat. J. Mol. Cell. Cardiol.42(4), 746–759 (2007).
   PubMed Web of Science ®Google Scholar
• Moelker AD, Baks T, Wever KMAM et al. Intracoronary delivery of umbilical cord blood derived unrestricted somatic stem cells is not suitable to improve LV function after myocardial infarction in swine. J. Mol. Cell. Cardiol.42(4), 735–745 (2007).
   PubMed Web of Science ®Google Scholar
• Zhou R, Thomas DH, Qiao H et al. In vivo detection of stem cells grafted in infarcted rat myocardium. J. Nucl. Med.46(5), 816–822 (2005).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell126, 663–676 (2006).
   PubMed Web of Science ®Google Scholar
• Park I-H, Zhao R, West JA et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature451, 141–146 (2008).
   PubMed Web of Science ®Google Scholar
• Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell131(5), 861–872 (2007).
   PubMed Web of Science ®Google Scholar
• Yu J, Vodyanik MA, Smuga-Otto K et al. Induced pluripotent stem cell lines derived from human somatic cells. Science318(5858), 1917–1920 (2007).
   PubMed Web of Science ®Google Scholar
• Mauritz C, Schwanke K, Reppel M et al. Generation of functional murine Cardiac myocytes from induced pluripotent stem cells. Circulation118, 507–517 (2008).
   PubMed Web of Science ®Google Scholar
• Narazaki G, Uosaki H, Teranishi M et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation118, 498–506 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson TJ, Martinez-Fernandez A, Yamada S, Perez-Terzic C, Ikeda Y, Terzic A. Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation120(5), 408–416 (2009).
   PubMed Web of Science ®Google Scholar
• Schenke-Layland K, Rhodes KE, Angelis E et al. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells26(6), 1537–1546 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang J, Wilson GF, Soerens AG et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ. Res.104(4), e30–e41 (2009).
   PubMed Web of Science ®Google Scholar
• Martinez-Fernandez A, Nelson TJ, Yamada S et al. iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ. Res.105(7), 648–656 (2009).
   PubMed Web of Science ®Google Scholar
• Blin G, Nury D, Stefanovic S et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J. Clin. Invest.120(4), 1125–1139 (2010).
   PubMed Web of Science ®Google Scholar
• Kuethe F, Richartz BM, Sayer HG et al. Lack of regeneration of myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans with large anterior myocardial infarctions. Int. J. Cardiol.97(1), 123–127 (2004).
   PubMed Web of Science ®Google Scholar
• Hill JM, Syed MA, Arai AE et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J. Am. Coll. Cardiol.46(9), 1643–1648 (2005).
   PubMed Web of Science ®Google Scholar